SETD2 loss-of-function uniquely sensitizes cells to epigenetic targeting of NSD1-directed H3K36 methylation
These findings unify genome-wide screening approaches with the latest genetic and pharmacologic modeling methodologies to reveal an entirely novel epigenetic approach to individualize therapies against a challenging loss-of-function SETD2 mutation in cancer.
Authors
- Jeong‐Heon Lee (ORCID: https://orcid.org/0000-0003-4007-9166)
- Louis Y. El Khoury (ORCID: https://orcid.org/0000-0002-8147-435X)
- Ryan T. Wagner (ORCID: https://orcid.org/0000-0002-6725-2064)
- Xiaoyu Pan (ORCID: https://orcid.org/0000-0002-5184-222X)
- Tomasz Cierpicki
- Jian Zhong (ORCID: https://orcid.org/0000-0001-7157-603X)
- Thai H. Ho (ORCID: https://orcid.org/0000-0003-0023-2939)
- Keith D. Robertson (ORCID: https://orcid.org/0000-0002-7508-3328)
- Jolanta Grembecka (ORCID: https://orcid.org/0000-0002-6180-9095)
- Ryan A. Hlady (ORCID: https://orcid.org/0000-0002-2829-4237)
- Xia Zhao (ORCID: https://orcid.org/0000-0001-8467-9513)
- Sungho Kim (ORCID: https://orcid.org/0000-0002-7004-3482)
- Liguo Wang (ORCID: https://orcid.org/0000-0003-2072-4826)
- Shafiq Shaikh
Institutions
- Mayo Clinic (US)
- Medical University of South Carolina (US)
- Medical College of Wisconsin (US)
- University of Michigan (US)
- MUSC Hollings Cancer Center (US)
Publication Details
- Journal
- Genome biology
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1186/s13059-025-03483-z
- Citations
- 7
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- U.S. Department of Defense
- National Institutes of Health
- Hollings Cancer Center, Medical University of South Carolina
- National Cancer Institute